AIM
RPRX icon

Axiom Investment Management’s Royalty Pharma RPRX Stock Holding History

Axiom Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$222K Buy
5,621
+1,100
+24% +$45.9K 0.58% 56
2022
Q3 		$182K Sell
4,521
-4,879
-52% -$208K 0.36% 58
2022
Q2 		$395K Buy
+9,400
New +$385K 1.14% 36

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axiom Investment Management's RPRX Position: Q4 2022 in Review

Axiom Investment Management increased its Royalty Pharma (RPRX) stake by 24% in Q4 2022, buying an estimated $45.9K and bringing the position to 5,621 shares worth $222K. The position accounts for 0.58% of the portfolio, ranked #56.

Axiom Investment Management first reported a position in RPRX in Q2 2022 and has held it in 3 quarters since. The position peaked at $395K in Q2 2022. 336 funds tracked by Wall St. Rank hold RPRX as of Q4 2022.

  • Axiom Investment Management held 5,621 shares of Royalty Pharma worth $222K as of Q4 2022.
  • Axiom Investment Management bought 1,100 Royalty Pharma shares in Q4 2022, an estimated $45.9K.
  • Royalty Pharma made up 0.58% of Axiom Investment Management's portfolio in Q4 2022, its #56 holding.
  • Axiom Investment Management first reported a position in Royalty Pharma in Q2 2022 and has held it in 3 quarters since.
  • Axiom Investment Management's Royalty Pharma position peaked at $395K in Q2 2022.
  • 336 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2022.

Based on Axiom Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.